|
|
Journal of Zhejiang University SCIENCE A
ISSN 1673-565X(Print), 1862-1775(Online), Monthly
2000 Vol.1 No.2 P.218-221
EFFECT OF NEBULIZED NITROGLYCERIN ON CHILDREN WITH VENTRICULAR SEPTAL DEFECT AND PULMONARY HYPERTENSION
Abstract: In order to find a safe, simple, effective and selective pulmonary vasodilator, we tested the effectiveness and safety of inhalation of nebulized nitroglycerin (Neb-NTG) by children with ventricular septal defect and pulmonary hypertension (VSD-PH). Twenty μg/kg Neb-NTG was inhaled by seven children with VSD-PH using face mask during cardiac catheterization. The pulmonary artery pressure (PAP), systemic arterial pressure (SAP) and methemoglobin (MetHb) concentration were measured before and after inhalation of Neb-NTG. After inhalation of Neb-NTG, the PAP and pulmonary-to-systemic pressure ratio (Pp/Ps) decreased significantly; There was no significant decrease in SAP. The systolic and diastolic PAP decreased respectively 13±4% and 9±7% in 5 min, 21±3% and 13±17% in 10 min, 24±3% and 16±19% in 15 min. The Pp/Ps decreased 12±4% in 5 min, 21±9% in 10 min and 24±6% in 15 min. There was no significant increase in the MetHb level after inhalation of 20 μg/kg of Neb-NTG. The MetHb level was below 1.5%. Neb-NTG is a safe, simple, effective and selective pulmonary vasodilator.
Key words: vasodilator, nitroglycerin, inhalation, pulmonary hypertension
References:
[1]Bush, A., Busst, C.M., Haworth, S.G., et al., 1988. Correlations of lung morphology, pulmonary vascular resistance, and outcome in children with congenital heart disease. Br Heart J. 59:480-485.
[2]Celermajer, D.S., Cullen, S., Deanfield, J.E., 1993. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation. 87:440-446.
[3]Chung, S.J., Fung, H.L., 1990. Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J Pharmacol Exp Ther. 253:614-619.
[4]Dinh-Xuan, A.T., Higenbottam, T.W., Clelland, C., et al., 1990. Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger's syndrome. Br J Pharmacol. 99:9-10.
[5]Feelisch, M., 1991. The biochemical pathways of nitric oxide formation from nitrovasodilators: appropriate choice of exogenous NO donors and aspect of preparation and handling of aqueous NO solutions. J Cardiovasc Pharmacol. 17(suppl 3):S25-S33.
[6]Furchtgott, R.F., Zawadzki, J.V., 1980. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetlycholine. Nature. 288:373-376.
[7]Hoffman, J.I.E., Rudolph, A.M., Heymann, M.A., 1981. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes. Circulation.64:873-877.
[8]Ignarro, L.J., Lippton, H., Edwards, J.C., et al., 1981. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates.J Pharmacol Exp Ther. 218:739-749.
[9]Loscalzo, J., 1992. Endothelial dysfunction in pulmonary hypertension. N Engl J Med. 327:117-119.
[10]Moncada, S., Radomski, M.W., Palmer, R.M., 1988. Endothelium-derived relaxing factor: identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol. 37:2495-2501.
[11]Palmer, R.M., Ferrige, A.G., Moncada, S., 1987, Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327:524-526.
[12]Perez-Vizcaino, F., Villamor, E., Duarte, J., et al., 1997. Involvement of protein kinase C in reduced relaxant responses to the NO/cyclic GMP pathway in piglet pulmonary arteries contracted by the thromboxane A2-mimetic U46619. Br J Pharmacol. 121:1323-1333.
[13]Prielipp, R.C., Rosenthal, M.H., Pearl, R.G., 1988. Vasodilator therapy in vasoconstrictor-induced pulmonary hypertension in sheep. Anesthesiology. 68:552-558.
[14]Rimar, S., Gillis, C.N., 1993. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation. 88:2884-2887.
[15]Salvemini, D., Pistelli, A., Vane, J., 1993. Conversion of glyceryl trinitrate to nitric oxide in tolerant and non-tolerant smooth muscle and endothelial cells. Br J Pharmacol. 108:162-169.
[16]Troncy, E., Jacob, E., da-Silva, P., et al., 1996. Comparison of the effect of inhaled nitric oxide and intravenous nitroglycerin on hypoxia-induced pulmonary hypertension in pigs. Eur J Anaesthesiol. 13:521-529.
[17]Van-Obbergh, L.J., Charbonneau, M., Blaise, G., 1996. Combination of inhaled nitric oxide with i.v. nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension. Br J Anaesth. 77:227-231.
Warren, J.B., Higenbottam, T., 1996. Caution with use of inhaled nitric oxide. Lancet. 348:629-630.
[18]Weir, E.K., Archer, S.L., Rubin, L.J., 1995. Pulmonary Hypertension. In: Willerson, J.T., Cohn, J.N., eds, Cardiovascular Medicine. Churchill Livingstone Inc. New York. p.1496-1497.
Open peer comments: Debate/Discuss/Question/Opinion
<1>
DOI:
10.1631/jzus.2000.0218
CLC number:
R725.4
Download Full Text:
Downloaded:
2705
Clicked:
5437
Cited:
0
On-line Access:
Received:
1999-05-12
Revision Accepted:
1999-12-20
Crosschecked: